A Phase 1, Multicenter, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of BIIB028 [CNF-3647] Administered to Subjects With Advanced Solid Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2017
At a glance
- Drugs BIIB 028 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 11 Jan 2017 Last checked against ClinicalTrials.gov record.
- 08 Dec 2011 Actual patient number is 43 as reported by ClinicalTrials.gov.
- 15 Sep 2011 Planned End Date changed from 1 Oct 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.